Medicine composition for treating hepatitis

A composition and drug technology, applied in the directions of drug combination, active ingredients of heterocyclic compounds, digestive system, etc., can solve problems such as difficulty in obtaining eradication of HBV

Inactive Publication Date: 2008-09-03
SINOPHARM A THINK PHARMA
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the replication of HBV in the body is a complex process, and it is difficult to achieve the effect of eradicating HBV with a single drug. Only by inhibiting the replication of HBV at multiple target sites can a good therapeutic effect be achieved.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] Example 1 1:1 composition of oxymatrine and ganciclovir

[0019] Mix equal amounts of oxymatrine and ganciclovir to obtain pharmaceutical composition 1. Composition 1 was prepared into the following various dosage forms.

[0020] 1-1. Preparation of injection

[0021] Take equal amounts of oxymatrine and 200 g of ganciclovir and mix each, add water for injection, and adjust the pH to 10-12 with sodium hydroxide to make a mixed solution containing 100 mg of oxymatrine and ganciclovir per milliliter, Add activated carbon for needles, stir for 10 minutes, let stand for 30 minutes, filter and decarburize, and fill the semi-finished solution after passing the test, each with a volume of 2ml.

[0022] 1-2. Preparation of tablets

[0023] Get equal amounts of oxymatrine and ganciclovir each 200g and mix, add microcrystalline cellulose 150g, granulate with 50ml of 10% PVP k-30 (50% ethanol solution), dry, granulate, weigh the granule weight, Add sodium carboxymethyl starch ...

Embodiment 2

[0034] Example 2 1:2 composition of oxymatrine and ganciclovir

[0035] 2-1. Preparation of injection

[0036] Mix 100 grams of oxymatrine and 200 g of ganciclovir, add water for injection, and adjust the pH to 10-12 with sodium hydroxide solution to make a mixed solution containing 100 mg of oxymatrine and 200 mg of ganciclovir per milliliter , add activated carbon for needles, stir for 10 minutes, stand for 30 minutes, filter for decarburization, and fill the semi-finished solution after passing the test, each with a volume of 2ml.

[0037] 2-2. Preparation of tablets

[0038] Get oxymatrine 100 grams and Ganciclovir 200g to mix, add microcrystalline cellulose 200g, granulate with 10% PVP k-30 (50% ethanol solution) 100ml, dry, granulate, weigh the granule weight, press 6% by weight of the granules is added with sodium carboxymethyl starch, and 2% by weight of the granules is added with magnesium stearate, compressed into tablets, coated, and made into tablets.

[0039] 2...

Embodiment 3

[0049] Example 3 Oxymatrine and Ganciclovir 2:1 Composition

[0050] Mix oxymatrine and ganciclovir at a ratio of 2:1 to obtain composition 3. Get oxymatrine 200g and ganciclovir 100g respectively according to the method of embodiment 1.

[0051] 3-1. Preparation of injection

[0052] Mix 200 grams of oxymatrine and 100 g of ganciclovir, add water for injection, and adjust the pH to 10-12 with sodium hydroxide solution to make a mixed solution containing 200 mg of oxymatrine and 100 mg of ganciclovir per milliliter , add activated carbon for needles, stir for 10 minutes, stand for 30 minutes, filter for decarburization, and fill the semi-finished solution after passing the test, each with a volume of 2ml.

[0053] 3-2. Preparation of tablets

[0054] Get 200 grams of oxymatrine and mix ganciclovir 100 g, add microcrystalline cellulose 50 g, granulate with 30 ml of 10% PVP k-30 (50% ethanol solution), dry, granulate, weigh the granule weight, press 2% by weight of the granu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to hepatitis treating medicine composition, and especially hepatitis treating lovir medicine composition. The lovir medicine composition contains lovir compound in 10-50 weight portions and Chinese medicine component matrine in 10-50 weight portions. The lovir compound and the matrine component result in excellent synergistic antiviral effect and less side effects, so that the lovir medicine composition has raised curative effect and lowered toxicity.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating hepatitis, in particular to a clovir pharmaceutical composition for treating hepatitis. Background technique [0002] Lowe drugs belong to nucleoside analogs, which can competitively inhibit viral DNA polymerase, directly incorporate viral DNA, and stop the extension of viral DNA. They are a class of antiviral hepatitis drugs with very obvious effects. However, there are certain adverse reactions in this class of drugs, so that the use of this class of drugs is subject to certain restrictions. Severe rebound phenomenon is prone to occur after taking this type of drug, which makes the disease relapse, which leads to the resistance of the virus to the drug, and can lead to neutropenia and thrombocytopenia. At the same time, this type of drug still exists It has certain nephrotoxicity and neurotoxicity. [Aciclovir Adverse Reactions, Journal of Adverse Drug Reactions, Issue 1, 2004] [Adve...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/522A61P1/16A61P31/20
Inventor 王振国贾志丹曹树煜吴素林
Owner SINOPHARM A THINK PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap